Transparency at Bayer

We publicly disclose new contract-based scientific collaborations of Bayer entities in Germany, the USA, Switzerland and Brazil with universities, public research institutions and individuals worldwide via the Bayer Science Collaboration Explorer (BSCE).

Bayer is fully committed to make information about its planned and ongoing clinical trials publicly available. This is done in line with the position of the global pharmaceutical industry associations and applicable laws and regulations. Bayer will also make results of trials in patients public and provide free access to this information on several publicly accessible Clinical Trial Registries on the internet, irrespective of whether the results of a trial for one of our products are positive or negative. Bayer is committed to sharing of study patient data with qualified researchers as a transparency measure to advance medical knowledge and public health and foster scientific discovery. Data sharing is following international standards to protect patient’s data privacy.

We disclose any financial commitments with healthcare professionals to ensure maximum transparency and safeguard medical integrity via our CRYSTAL database.

We aim to remove barriers to obtaining detailed information on the safety of our products by enabling access to product safety information and regulatory submission documents in parallel with background materials and information on our rigorous crop safety standards. We are also sharing our internal product safety standards to shed light on how we determine how products can be used safely here. With our European Small Breeders Initiative we provide additional transparency for small vegetable breeding companies in the EU and facilitate their access to innovation.

We are opening our doors via our Crop Science OpenLabs program, allowing people to connect with our scientists and watch them carry out a safety study live in our labs and in the field.

We provide regular and timely information on the Group’s position and significant changes in business activities to shareholders, financial analysts, the media, and the general public. 

We disclose detailed information on our political activities in the transparency registers operating by the European Union, the U.S. Congress and the German Parliament (Bundestag). We also publish our key political positions on our website and, as of 2023, publish an annual political advocacy transparency report.

We are committed to respecting and fostering human rights within our business activities and in business relations and to reporting transparently on the results of our activities in this area. For more information, please see our Sustainability Report.

We support charitable projects that focus on achieving Health for All, Hunger for None – our donations are made transparent in our annual Sustainability Report.

In our Sustainability Report, we also showcase how our operations affect the environment and how much natural resources we consume, e.g., concerning freshwater. Our sustainability efforts are also examined by an independent Sustainability Council that regularly reports (PDF, 0,74MB) on its progress and priorities.

We regularly assess and disclose the alignment of our industry associations’ climate positions with our commitments on climate change. For more information, please see our Industry Association Climate Review 2021 (PDF, 6,3MB).

We increase transparency and visibility of Bayer’s innovative research activities within the external scientific community through our Science in Spotlight platform, listing peer-reviewed scientific publications authored by Bayer employees.